These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 10143664)
1. Drug testing from a patient's perspective. Stehlin IB FDA Consum; 1995 Mar; 29(2):6-7. PubMed ID: 10143664 [No Abstract] [Full Text] [Related]
2. The special treatment. Osborne R Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770 [No Abstract] [Full Text] [Related]
3. Errors in 'Trials and error'. Miller DD Nat Biotechnol; 2006 Jul; 24(7):747. PubMed ID: 16841048 [No Abstract] [Full Text] [Related]
4. Dosing strategies for antidepressant clinical trials: a commentary. Robinson DS; Khan A J Clin Psychopharmacol; 2004 Feb; 24(1):1-3. PubMed ID: 14709939 [No Abstract] [Full Text] [Related]
5. A piece of history. Nat Biotechnol; 2003 Aug; 21(8):831. PubMed ID: 12894179 [No Abstract] [Full Text] [Related]
6. Translation of cancer immunotherapies. Skipper J; Hoffman EW; O'Donnell-Tormey J; Old LJ Nat Med; 2004 Nov; 10(11):1154-5; author reply 1155. PubMed ID: 15516901 [No Abstract] [Full Text] [Related]
7. The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents. Powers JH; Ross DB; Brittain E; Albrecht R; Goldberger MJ Clin Infect Dis; 2002 Mar; 34(6):879-81. PubMed ID: 11850875 [No Abstract] [Full Text] [Related]
8. Metabolites in safety testing: "MIST" for the clinical pharmacologist. Frederick CB; Obach RS Clin Pharmacol Ther; 2010 Mar; 87(3):345-50. PubMed ID: 20107437 [No Abstract] [Full Text] [Related]
9. Benefit the patient, manage the risk: a system goal. Califf RM Pharmacoepidemiol Drug Saf; 2004 May; 13(5):269-76. PubMed ID: 15133777 [No Abstract] [Full Text] [Related]
10. Is it time to rethink the expanded-access programs for HIV infection? Amorosa V; Tebas P J Infect Dis; 2007 Oct; 196(7):974-7. PubMed ID: 17763316 [TBL] [Abstract][Full Text] [Related]
11. They are from the government and they really are here to help you. Woosley RL J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889 [No Abstract] [Full Text] [Related]
12. Editorial: Adaptive designs: appealing in development of therapeutics, and where do controversies lie? Wang SJ J Biopharm Stat; 2010 Nov; 20(6):1083-7. PubMed ID: 21058102 [No Abstract] [Full Text] [Related]
13. Communicating with the FDA: the "third rail" of a new model for drug development. Stanski DR; Orloff JJ J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890 [No Abstract] [Full Text] [Related]
14. Conflating the approval process and clinical research with pharmacoeconomic evaluation. Somberg JC Am J Ther; 2013 Jan; 20(1):1. PubMed ID: 23299228 [No Abstract] [Full Text] [Related]
15. To market, to market. The nuts and bolts of prescription drug approval. Peterson AM Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443 [No Abstract] [Full Text] [Related]
16. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Peck CC; Rubin DB; Sheiner LB Clin Pharmacol Ther; 2003 Jun; 73(6):481-90. PubMed ID: 12811358 [No Abstract] [Full Text] [Related]
17. Ethical issues in pediatric trials. Ross LF; Newburger JW; Sanders SP Am Heart J; 2001 Aug; 142(2):233-6. PubMed ID: 11479460 [No Abstract] [Full Text] [Related]
18. The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. Brass EP Clin Pharmacol Ther; 2010 Mar; 87(3):351-5. PubMed ID: 20010554 [No Abstract] [Full Text] [Related]
19. [The inspection by the Danish Medical Products Agency of drug clinical trials]. Jacobsen E; Stilbo I Ugeskr Laeger; 2003 Apr; 165(16):1656-8. PubMed ID: 12756822 [TBL] [Abstract][Full Text] [Related]
20. Medical research on humans: regulation in Switzerland, the European Union, and the United States. Schott M Food Drug Law J; 2005; 60(1):45-77. PubMed ID: 15940854 [No Abstract] [Full Text] [Related] [Next] [New Search]